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Abstract
Introduction: Acute liver failure is a rare disease with high mortality and liver transplantation is the only life saving therapy.
Accurate prognosis of ALF is crucial for proper intervention.
Aim: To identify and characterize newly developed prognostic models of mortality for ALF patients, assess study quality,
identify important variables and provide recommendations for the development of improved models in the future.
Methods: The online databases MEDLINEH (1950–2012) and EMBASEH (1980–2012) were searched for English-language
articles that reported original data from clinical trials or observational studies on prognostic models in ALF patients. Studies
were included if they developed a new model or modified existing prognostic models. The studies were evaluated based on
an existing framework for scoring the methodological and reporting quality of prognostic models.
Results: Twenty studies were included, of which 18 reported on newly developed models, 1 on modification of the Kings
College Criteria (KCC) and 1 on the Model for End-Stage Liver Disease (MELD). Ten studies compared the newly developed
models to previously existing models (e.g. KCC); they all reported that the new models were superior. In the 12-point
methodological quality score, only one study scored full points. On the 38-point reporting score, no study scored full points.
There was a general lack of reporting on missing values. In addition, none of the studies used performance measures for
calibration and accuracy (e.g. Hosmer-Lemeshow statistics, Brier score), and only 5 studies used the AUC as a measure of
discrimination.
Conclusions: There are many studies on prognostic models for ALF but they show methodological and reporting
limitations. Future studies could be improved by better reporting and handling of missing data, the inclusion of model
calibration aspects, use of absolute risk measures, explicit considerations for variable selection, the use of a more extensive
set of reference models and more thorough validation.
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Introduction
Acute liver failure (ALF), also known as fulminant hepatic
failure (FHF), is a rare disease associated with a very high mortality
ranging from 60 to 90% depending on the etiology and the clinical
experience of the reference center [1]. An early and exact
assessment of the severity of ALF together with a prediction of its
further development is critical in order to determine the further
management of the patient. Spontaneous recovery occurs in a
minority of patients. Although liver support devices can be
considered as a temporary treatment, in most cases liver
transplantation (LT) remains the only life saving treatment of
irreversible ALF [2]. LT has been shown to improve outcome,
achieving survival rates up to 80% [3]. The timely prediction of
spontaneous recovery helps prevent LT and also the need for
lifelong immunosuppressive therapy. Timely assessing the likeli-
hood of mortality is important for decisions on emergency liver
transplantation. Due to severe shortage of liver donors it is of
utmost importance to distinguish patients requiring transplanta-
tion from those who will survive by receiving only intensive
medical care. Predicting whether the patient with ALF will require
transplantation or will recover with medical management alone is
difficult.
A number of prognostic models have been used for outcome
prediction in ALF patients to select patients in need of LT. The
most widely applied ones are the King’s College criteria (KCC),
Clichy criteria, and the Model for End-Stage Liver Disease
(MELD), which was originally developed to estimate post-
PLOS ONE | www.plosone.org 1 December 2012 | Volume 7 | Issue 12 | e50952
procedural mortality in cirrhotic patients undergoing transjugular
intrahepatic porto-systemic shunts (TIPS) [1], [4], [5]. The models
have shown inconsistent reproducibility, prognostic accuracy and
therefore cannot be taken to reliably predict mortality in ALF and
the need for a better prognostic model remains [6], [7], [1]. Other
prognostic models originally developed to measure the severity of
illness for patients admitted to intensive care units, like the Acute
Physiology and Chronic Health Evaluation II (APACHE II),
Sequential Organ Failure Assessment (SOFA) and Simplified
Acute Physiology Score III (SAPS III) also have been applied in
ALF patients. Cholongitas et al. [8] showed that scores used to
quantify severity of illness such as APACHE II or to monitor organ
dysfunction like SOFA can be also used as early prognostic
markers in ALF patients. A recent comparison among KCC,
MELD, SOFA and APACHE II scores in patients with
acetaminophen-induced acute liver failure concluded that KCC
had the highest specificity (0.83) but lowest sensitivity (0.47) and
SOFA had the best discriminative ability (Area Under the
Receiver Operating Characteristic curve, AUC=0.79) [9].
McPhail et al. in a recent meta-analysis [10] considered aspects
of methodological quality of studies reporting the performance of
only the KCC model and restricted the analysis to only
acetaminophen-induced ALF. Other validation studies of the
most widely applied models (such as KCC, Clichy criteria, MELD)
can be found in the literature [1], [4], [11], [12]. However, to date
there is no systematic review on the newly developed prognostic
models for ALF patients.
The objective of this review was to identify and characterize
prognostic models developed to predict mortality of ALF patients,
and assess the quality of their respective studies. In addition, we
identify the variables used for development of the models. Our
review provides recommendations for future research on predic-
tion models for ALF patients.
Methods
Search strategy and data sources
We re-used the search strategy employed in our prior published
systematic review on ALF definitions [13]. Briefly, Ovid
Embase(R) (1980 to 2012), Ovid MEDLINE(R) (1950 to 2012)
and Ovid MEDLINE(R) In-Process & Other Non-Indexed
Citations (1950 to 2012) for journal articles were searched based
on keywords in title, abstract and MeSH terms. The following
query was used: (prognosis OR prognostic OR predict*) AND
(acute liver failure OR fulminant hepatic failure OR acute liver
injury OR acute hepatic failure OR (acute on chronic AND liver
failure)). ‘‘Liver failure’’ and ‘‘prognosis’’ were used as MeSh
terms. The final search considered studies published up to 01
January 2012.
Inclusion and exclusion criteria
We included articles only when they reported original data from
a clinical trial or observational study on patients with ALF and if
one of their main objectives was either developing one or more
new prognostic models or modifying existing ones for predicting
outcome (mortality/survival or LT) for ALF patients. Validation
studies (defined as studies that validated the performance of earlier
published models, without modification, on new data sets)
assessing the performance of the established prediction models
KCC, MELD, and Clichy criteria were excluded.
All duplicate articles resulting from the query above were
removed and only English articles were considered. In the first step
we excluded conference abstracts, paper reviews, comments and
case studies. In the next step irrelevant studies were excluded
based on titles and abstracts, followed by exclusion of the
remaining studies based on their full text.
Two reviewers independently screened the titles and abstracts.
Discrepancies between the 2 reviewers were resolved by consensus
involving a 3rd reviewer. Figure S1 displays the search flowchart.
Data collection and analysis
The studies that were included were classified as either
developing a new model or modifying an existing model. A study
developing a new model was termed a development study, in that it
described and assessed the performance of a prediction model that
had not previously been published. Development studies had to
include at least one newly developed model, but may also have
included other established existing models, such as the KCC,
MELD, Clichy criteria, or any other more recently developed
model for comparison. A study was classified as modifying an
existing model if it described and assessed a modified version of a
previously published model by, for example, adding or removing
variables.
For each of the included studies, the general study character-
istics (e.g. setting, study year, inclusion criteria, outcome and
patients’ characteristics) and model characteristics (e.g. the
reported intended use of the prognostic model, technique(s) used
for development and performance and validation of the model)
were extracted. The quality of the study was reported using a
structured data collection form as proposed by Medlock et al. [14].
As before, two reviewers extracted and summarized data and
scored the methodological and reporting quality. Discrepancies
between the reviewers were resolved by involving a 3rd reviewer.
Prediction models
We distinguished two types of prediction models: regression
models (e.g. survival Cox model, linear or logistic model); or
decision models (e.g. a decision tree, discriminant analysis, or a
decision rule based on a score variable). For the description of the
models we recorded: the timing of variable measurement (e.g. at
admission or peak value during some interval), type of prediction
model, strategy of model development and the final model itself in
the form of a prognostic formula or a decision rule.
Variables
All input variables (potential predictors or confounders that
were considered during model development), also known as
covariates, were listed for each prediction model. We also report
on the final input variables that remained in the final model after
employing a variable elimination strategy.
Prognostic performance measures
The performance measures were divided into the following 4
categories:
1) Statistical measures of performance based on a given cut-off
point that result in a binary prediction (0 or 1): sensitivity,
specificity, positive predictive value (PPV), negative predic-
tive value (NPV), predictive accuracy (PA), positive likeli-
hood ratio (PLR) and negative likelihood ratio (NLR).
2) Discrimination measures assessing the ability of the model to
assign higher predicted probabilities of the outcome (e.g.
death or LT) in patients actually having the outcome than
those not having it. The most common measure is the AUC
(Area Under the Receiver Operating Characteristic (ROC)
curve).
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3) Calibration measures assessing the proximity between the
predicted probabilities and the actual risk of a group of
similar patients. For example, the model was considered to
be well calibrated when 25% of patients with a predicted
mortality of 25% did indeed have the event. Common
measures of (mis)calibration are the Hosmer-Lemeshow
statistics.
4) Accuracy measures assessing the average proximity of a
predicted probability for an individual patient to his/her
actual outcome. These include elements of both discrimi-
nation and calibration [15] and are typically measured by
the Brier score or Brier skill score (which is the proportion of
explained variance).
We required that a study report on at least 2 of the above-
mentioned performance categories in order to score positively in
the quality assessment framework on model performance.
Validation pertains to assessing the statistical performance of a
model. In order for prognostic models to be used in clinical
practice they need to be credible, and validation is an important
component for reinforcing model credibility. Apparent validation
(estimating performance on the same sample from which the
model was developed) may be biased due to leveraging on
coincidental correlations in the development sample. For studies
developing new models it is imperative to at least internally
validate them. Internal validation means estimating the perfor-
mance that would be obtained from a different sample but from
the same population of the developmental dataset. This can be
obtained by either estimating performance on a separate reserved
subsample from the developmental sample or by resampling
techniques from the developmental set using bootstrap or cross-
validation techniques. Validation performed on a separate
prospective dataset from the same setting is called temporal
validation, and validation on a dataset in a different setting is
called external validation [16].
Quality assessment
The framework proposed by Medlock et al. [14] which was in
part based on Minne et al. [17] and Hayden et al. [18] was used for
assessment of the quality of content of the studies and the
assessment of the performance of the models.
The framework has two sections: a reporting quality section for
assessing the quality of reporting in the study, and a methodolog-
ical section consisting of a number of questions assessing the rigor
of model development and validation.
The reporting score consisted of 19 items (38 possible points)
including description of study population, choice of predictors/
variables to test, missing data, outcome measure and model
description including its intended use and performance measures.
The methodological score consisted of 6 items (12 possible
points) including a sufficient number of cases to support the
number of variables, a representative population and validation.
Each item in the framework was rated as no (N, with 0 points),
partly (P, with 1 point), or yes (Y, with 2 points). For example, the
setting and study period should be reported to score 2 points and
when only one is reported it scores 1 point.
The higher the score in each part of the framework was
considered as higher quality of the study in that part.
Results
Study characteristics
Searching the online databases resulted in 1233 articles. Initial
screening of titles and abstracts resulted in 125 articles for full text
review, of which 20 articles met our inclusion criteria and were
included in this review.
Detailed characteristics of these studies are presented in Table
S1. The smallest and largest study included 23 and 588 patients,
respectively. Mean (SD) and median [IQR] of sample size was 159
(164) and 99 [60–171], respectively.
In one study, gender was not reported (17% of patients), and
59% of patients were female among the remaining studies.
Five studies were conducted prospectively, 6 studies retrospec-
tively and in 9 studies the data collection method was not reported.
Model characteristics
Models. The included studies reported on 46 models.
Eighteen studies proposed 26 new models and were considered
as development studies. In one study the modification of an
existing model, the KCC and in one other study the MELD were
proposed. These models are described in Table S1. Models were
developed to predict mortality (11 studies), survival (3 studies),
need for transplantation (2 studies), and the combined outcome of
death or transplantation (in 4 studies).
The majority of the studies used logistic regression analysis (14/
20), 3 used Cox regression ([19], [20], [21]), 1 used both logistic
and Cox regression [22], 2 used linear regression ([23], [24]), and
1 discriminant analysis [25]. Most of the newly developed models
used variables measured at admission; some studies ([3], [26], [27])
used both the admission and peak values of variables during
admission. One study used variables measured at the time of onset
of grade 3–4 HE [28], 1 study [29] at the time of diagnosis
(defined as the time when the patient fulfilled the diagnostic
criteria of ALF, in Japan), 1 study [24] at days 1, 4, 8 and 15
following diagnosis, and 1 study [20] at the time of testing the
serum sample for IgM anti-HBc.
Three studies performed temporal validation of the model’s
predictive performance using a second cohort of patients from the
same hospital admitted after those in the development set. One
study performed internal validation of the model using the
resampling technique of leave-one-out where for each patient P
a model is developed based on all other patients and tested on P
[25]. The remaining studies did not perform any internal,
temporal or external validation of the predictive performance of
their models.
The most common performance measures reported in the
studies were: sensitivity, specificity, PPV or NPV (16 studies). The
thresholds in these performance measures depended on specific
covariate patterns, instead of absolute probabilities. For example,
in a model with three risk factors, 3 PPVs were calculated
corresponding to patients having any one, or any two, or all risk
factors. The next most commonly used performance measure was
the AUC (5 studies). None of the studies used Hosmer-Lemeshow
statistics, the Brier score or the Brier skill score.
Variables. Table S2 in the supplement lists 103 prognostic
indicators (input variables) that were considered as potential
predictors in the developed models. The table also includes the
cut-off values for obtaining categorical indicators from continuous
ones, which varied among studies; otherwise, the indicator was
used as a continuous variable. Table 1 lists the indicators
considered in more than ten studies in addition to the number
of studies in which the indicator was categorized. The most
commonly used indicator was bilirubin (16 times), which was
selected in 8 final models. Twenty-three of 103 variables were use
as categorical variables. The most commonly categorized variable
was prothrombin time (PT, 10 times).
Quality assessment framework. Table S3 in the supple-
ment shows the scores of each study in terms of reporting and
Systematic Review of ALF Prediction Models
PLOS ONE | www.plosone.org 3 December 2012 | Volume 7 | Issue 12 | e50952
methodological quality. Reporting scores ranged from 17 to
30 points (median 24 out of a maximum of 38). Items scoring
lower on reporting quality pertain to lack of reporting on missing
values, on performance measures, and on reporting predicted
probabilities or mortality percentages for covariate patterns for at
least two specific groups of patients. Only 6 studies reported
missing values, four of which reported on the way they were
handled, and only one quantified the number of missing values.
Other items scoring lower include giving the reason for the choice
of the initial variables in the model and reporting on the spread of
the primary outcome measure (confidence intervals). The best
scoring items of the reporting score include reporting on patients’
characteristic, defining and including important variables, and
reporting on the intended use and a type of the model.
Methodological scores ranged from 7 to 12 points (median 10)
out of a maximum of 12. Validation was performed in only 4
studies (3 studies used temporal validation and 1 used internal
validation relying on the leave-one-out method). The best scoring
items of the methodological part of the framework was reporting
on the number of patients, number of events and number of
variables.
For example, for the first item of the methodological score study
by Hadem et al. [23] a score of 2 points ( =Y, Yes) was assigned
since the number of events per variable in the final model was
sufficient (.10). Study [30] received 1 point ( = P, Partially) since
the number of events per variable was between 5 and 10 and study
[19] received 0 points ( =N, No) because this ratio was below 5.
The number of events is defined as the minimum of the number of
ALF cases and non-cases. The study by Hadem et al. [23] scored
on almost all items of the methodological score the maximum
2 points, except for the validation of the model, for which it
received 0 points. Points scored for each item were summed up
and the maximum attainable methodological score was 12 and for
the reporting score 38.
In an additional sub-analysis (not shown, available from the
corresponding author) we investigated the association between the
quality scores and each of year of publication, number of article
citations, and (current) impact factor of the journal where the
study was published. There was a positive significant association
between the year of publication and the reporting (but not the
methodological) quality score. This was most pronounced after
2005 (mean reporting score till 2005 was 21.7 and after 2005 was
26.9). There were no relevant associations between journal impact
factor or citations with the (methodological and reporting) quality
scores.
Comparison to other models. Ten studies, next to devel-
oping at least one new model, simultaneously compared the new
models to other existing historical models such as the KCC,
MELD, SAPS III and SOFA, but never to another recently
developed model. The most often reported reference model was
KCC (10 studies), followed by MELD (5 studies), SAPS III and
SOFA (each 1 study). Performance superiority was based simply
on showing that one or more of the following measures was larger
than those of the reference model: sensitivity, specificity, PPV,
NPV, PA, PLR, NLR (9 studies; reference model was KCC in 9
studies, MELD in 5 studies, SOFA in 1 study); or on AUC (3
studies; reference model was KCC in 3 studies, MELD in 3
studies, SAPS III in 1 study). All those studies declared that their
models were better than the established models. One study [29]
showed that the reference model (KCC), when used as a covariate
together with CTLV/SLV (ratio computed tomography-derived
liver volume/standard liver volume) was not statistically signifi-
cantly (p,0.05) associated with the outcome. This study suggested
also that the model based on CTLV/SLV was not inferior to
MELD and KCC in terms of sensitivity, specificity, PPV, NPV,
PA as reported in the literature.
Discussion
Principal findings
In this review we identified, summarized and assessed the
quality of available models in the literature for prediction of poor
outcome in adult patients with ALF. There is a marked
heterogeneity in the included studies and models (shown in Table
S2 in the supplement) in terms of: variability of the characteristics
of included populations, inclusion criteria, mortality rates,
outcome (inclusion or exclusion of transplanted patients), consid-
ered predictors, and choice of reference models for comparison.
Of note, 45% of the studies did not report whether data were
collected prospectively or retrospectively. Although all studies
aimed at including ALF patients, the definition of this disease
differs among studies [13]. Despite this heterogeneity some general
remarks can be made.
Model development usually relied on regression analysis,
including logistic, linear or Cox regression (survival analysis).
The models were usually constructed from clinical and/or
demographic data to predict mortality or survival, only four
studies used the combined outcome of death and transplantation.
Generally the intended use of the developed models was clear,
namely supporting decisions on whether to perform transplanta-
tion. However, half of the studies included small samples (,100
patients) and performed no internal, temporal or external
validation. None of the studies reported on how well the model
was calibrated. This is notable, as decision makers need to know
how well a predicted probability corresponds to the true risk in the
population. All studies comparing newly developed models with
Table 1. Summary of the most often studied indicators (n = number of studies).
Indicator Considered for developing the model (n) Selected in the final model (n)* Represented as categorical (n)
Bilirubin total 16 8 9
Age 15 8 8
HE 15 9 9
PT 14 9 10
Creatinine 13 5 5
Sex 13 1 -
ALT 11 1 2
*if a study reported more than 1 model, a variable selected in at least 1 model was counted one time.
doi:10.1371/journal.pone.0050952.t001
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the ‘‘standard’’ models like MELD and/or KCC, SOFA and
SAPS reported improved performance on these established models
based on sensitivity, specificity, PPV, NPV, PA, PLR, and NLR.
However, only 3 studies used additionally the AUC, and there are
no calibration-related comparisons. Surprisingly the commonly
used Clichy criteria were not used as a reference standard in the
included studies. In general the apparent arbitrariness of selecting
the reference models raises concerns about reporting bias. It will
be useful when future studies attempt to compare the developed
models to a standard set of other published reference models,
including newly developed ones, for the same population.
Strengths and limitations
To our knowledge this is the first systematic review exclusively
dedicated to the assessment of the performance of newly
developed prognostic models for adult patients with ALF. In our
former review [13] we reported that there is a wide diversity in
ALF definitions used in the literature, which hinders comparability
and quantitative analysis among studies. In this review we
identified and characterized newly developed prognostic models
of mortality for ALF patients and assessed the quality of their
respective studies. Our search has been extensive and we used an
earlier published framework for quality assessment [14].
In the systematic review by Craig et al. [31] 14 studies were
included which test the association of variables with poor outcome
in paracetamol-induced ALF patients. The quality of these studies
were assessed semi-quantitatively using a coarse grading system
(poor, moderate, good or excellent) along six potential sources of
bias in prognostic studies [18]. Another recent meta-analysis by
McPhail et al. [10] assessed the quality of studies validating KCC
and restricted to acetaminophen-induced ALF. These studies are
excluded in our review. Our review included studies pertaining to
ALF patients independently of aetiology; it extends the quality
assessment framework in [12] and distinguishes between reporting
and methodological quality; it includes only prognostic models,
not merely tests of pre-selected variables; and it considers newly
developed models rather than validation of existing ones.
We intentionally excluded external validation studies like [1]
and [4] since these would correspond to the already established
models (MELD, KCC, Clichy Criteria) and there are already
existing reviews on those models such as [10], [11], [12], [32]. In
our review we did include the studies on the development of KCC
[27] and Clichy Criteria [20] for ALF patients. There is no journal
paper describing the development of the MELD for ALF patients.
MELD has been primary designed to estimate short-term post-
procedural mortality of cirrhotic patients undergoing transjugular
intrahepatic portosystemic shunt [33], and later in patients with
end-stage chronic liver disease of diverse aetiology and severity
[34]. In 2002 MELD was implemented in the USA by the United
Network for Organ Sharing for organ allocation in patients with
chronic liver disease awaiting LT [21]. In 2003 in a conference
abstract Aydin et al. [35] suggested that MELD can be used as a
complementary tool to predict prognosis in ALF patients. MELD
received increasingly more attention and was applied as predictor
for ALF patients [21]. We hence consider this latter paper as the
first one officially dedicated to ALF patients and included in our
review.
Implications and recommendations
In order to be clinically useful, predictive models need to be
credible. This credibility is largely dependent on the model
validity. As reported by Cook [15] evaluation of models for
medical use should take the purpose of the model into account.
Evaluation of prognostic models should not be confined to only
ROC curve analysis, but should assess various relevant perfor-
mance measure covering at least both discrimination and
calibration.
Validation of a model is necessary to provide evidence of its
potential to accurately predict outcomes especially at the
individual patient level. As reported by Altman et al. [36] un-
validated models should not be used in clinical practice. However,
our review revealed that the great majority of models have not
even been internally validated nor has their calibration been
assessed. Surprisingly, only four studies [37], [24], [27], [25]
performed some form of validation of their models. Future studies
should provide calibration performance assessment (using e.g. the
Hosmer-Lemeshow goodness-of-fit statistics or, even better, the
Brier score) and should undergo adequate internal validation, a
good choice would be the use of bootstrap techniques to this end.
Moreover, in an additional search we found than none of these
models has been externally validated elsewhere.
Many studies (e.g. [29], [24]) have considered the transplanted
patient group and non-survivors in one group. Patients who
receive transplantation may consist of the most severe cases and
would have died without transplantation. Those transplanted
patients are probably similar to those who do not survive. A
separate analysis should be performed to compare the transplan-
tation patient characteristics to the non-survivor group, like in the
study of Dabos et al. [38]. When the groups are similar one can
consider forming the group with the combined outcome ‘‘trans-
planted or died,’’ at least for sensitivity analysis.
In the literature different kinds of models are applied, like
logistic regression or Cox regression. One should consider the aim
of the study when developing a model. Logistic regression is
appropriate when the aim of the study is prediction of an event
(mortality or survival) without regard to how long it took for the
event to occur. When the aim of the study is to predict the time
until event occurrence then the Cox regression is an appropriate
choice.
Most of the studies did not report on missing data. Only five
studies [3], [27], [37], [38], [39] reported how they handled the
missing values. Excluding cases with missing values reduces the
sample size and can bias the results. One should compare cases
with missing and non-missing values on other known variables to
check for bias. In addition (multiple) imputation of the missing
variables should be considered [40].
There was marked heterogeneity in the included variables. The
majority of the evaluated variables where used only once (65/99).
The reason for choosing the initial variables was often not clear.
Only four studies [3], [20], [28], [29] stated this reason. Selection
of the variables entered into the multivariate analysis was mostly
based on the significant results from univariate analysis. When the
number of variables is not excessive one should consider whether
variable selection is required, and if so, consider using an
information criterion (such as the Akaike Information Criterion)
in the (e.g. stepwise) selection process instead of relying on p-values
#0.05 in univariate analysis.
Many studies did not report why and how the continuous
variables were categorized. Categorization causes information loss
and has consequently less precise coefficient estimation and
reduced statistical power to detect an association between the
variable and patient outcome. For example, in the study of Tylor et
al. [19] when creatinine was considered as a continuous variable it
was significantly associated with mortality in univariate analysis,
but not when it was used as a categorical variable. Categorization
of continuous variables without compelling reasons should hence
be avoided. If categorization is unavoidable then the choice for the
cut-off points should be motivated.
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Because many variables indicate categories, or are represented
as such, most models will have only a small set of different
predicted probabilities. For example when using 2 binary variables
in the model there are at most 4 discrete different predicted
probabilities and no continuous range. Continuity in the predicted
probability would allow models to exhibit smooth behaviour in
which small changes in the covariate values are reflected by small
changes in the outcome. This leads to better distinctions among
patients.
In our systematic review we extracted variables which were used
for constructing the models (Table S2). These variables comprise a
huge number of possible predictors. Based on clinical experience
and from a theoretical point of view we would suggest to include
variables involved in the pathophysiology of ALF as well as age
and grade of HE. Specifically the following variables may be
considered: plasma ammonia, which rises as a consequence of
impaired hepatic urea synthesis and contributes to the develop-
ment of HE; plasma bilirubine, which increases as a consequence
of impaired biliary excretion and coagulopathy as a consequence
of decreased protein synthesis, especially of clotting factors,
expressed by INR. We also think that some aspect of impaired
capacity of the ALF patient to maintain metabolic homeostasis
should be considered. In this respect plasma lactate might be
relevant. In addition the biomarkers of the inflammatory response
of ALF might be considered: e.g. plasma ratio of IL6/IL10.
Due to the methodological and reporting quality limitations
generally encountered in the included studies we would recom-
mend to develop new models that consider most important
relevant variables and follow the methodological and reporting
recommendations presented in this study. The predictive perfor-
mance (and hopefully clinical value) of such models will need to be
tested in prospective large cohorts of ALF patients with different
etiologies.
In our sub-analysis we concluded that there was no relevant
association between any of impact factor and citations with any of
the quality of methodological and reporting score but that there
was a clear positive association between year of publication and
reporting score.
Conclusion
This systematic review provides an overview of models for
prediction of poor outcome in patients with acute liver failure.
These prognostic models were developed to support clinicians’
decisions, but they should be improved before being clinically
useful. Future studies could be improved by paying more attention
to (internal) validation, the inclusion of model calibration aspects,
better consideration of the transplantation patient group, better
reporting and handling of missing data, use of absolute risk
measures, explicit considerations for considering and selecting
predictors, the use of a more extensive set of reference models, and
the inclusion of continuous variables without categorizing them, as
well as clear reporting on the study design. It is hoped that the
results of this review can be useful for developers of future
prognostic models for ALF patients.
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